In this Issue:
Dasatinib vs. imatinib in newly diagnosed CML
Access to transplant for ethnic minorities
Idelalisib in double-refractory indolent B-cell NHL
Idelalisib + rituximab for previously treated CLL
Outcome and risk assessments for hospital-associated VTE
Chlorambucil + obinutuzumab or rituximab in CLL with comorbidities
Novel aspirin analogue resensitises leukaemia cells to fludarabine
Low-dose rituximab in ITP and warm AIHA
Dietary vitamin K and pharmacological activity of rivaroxaban
IgG level correlates with infection risk in CLL
Whole genome array screening as a front-line test in MM
PET imaging for treatment stratification of stage I–II HL
OS related to comorbidity/ performance status in elderly high-IPI DLBCL
Please login below to download this issue (PDF)